Matching articles for "mNEXSPIKE"
COVID-19 Update: 2025-2026 Vaccine Formulations and Recommendations
The FDA has licensed new 2025-2026 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax, mNEXSPIKE) and the adjuvanted protein subunit COVID-19 vaccine…
Med Lett Drugs Ther. 2025 Oct 13; 67(1739):166-8 doi:10.58347/tml.2025.1739d
The FDA has licensed new 2025-2026 formulations of the mRNA COVID-19 vaccines manufactured by Pfizer/BioNTech (Comirnaty) and Moderna (Spikevax, mNEXSPIKE) and the adjuvanted protein subunit COVID-19 vaccine manufactured by Novavax (Nuvaxovid) . The new formulations are indicated for use in all adults ≥65 years old and in persons 6 months (Spikevax) , 5 years (Comirnaty) , or 12 years (mNEXSPIKE, Nuvaxovid) through 64 years old who are at high risk for severe COVID-19 because of an underlying condition. An Emergency Use Authorization allowing administration of the Pfizer vaccine to children 6 months through 4 years old has been withdrawn.
COVID-19 Update: mNEXSPIKE — A New Moderna mRNA Vaccine for COVID-19
The FDA has licensed mNEXSPIKE (Moderna), an mRNA vaccine, for prevention of COVID-19 in adults ≥65 years old and in persons 12-64 years old who have a condition that puts them at high risk for severe…
Med Lett Drugs Ther. 2025 Jul 21; 67(1733):119-20 doi:10.58347/tml.2025.1733h
The FDA has licensed mNEXSPIKE (Moderna), an mRNA vaccine, for prevention of COVID-19 in adults ≥65 years old and in persons 12-64 years old who have a condition that puts them at high risk for severe outcomes from COVID-19. Spikevax , the original Moderna mRNA COVID-19 vaccine, remains in production2; it is licensed for use in persons ≥12 years old and is available under an Emergency Use Authorization (EUA) for children 6 months to 11 years old.
